Activation of the central cholinergic system mediates the reversal of hypotension by centrally administrated U-46619, a thromboxane A2 analog, in hemorrhaged rats

Simple item page
dc.contributor.buuauthorYalçın, Murat
dc.contributor.buuauthorÇavun, Sinan
dc.contributor.buuauthorYılmaz, Mustafa Sertaç
dc.contributor.buuauthorSavcı, Zahide
dc.contributor.departmentUludağ Üniversitesi/Veteriner Fakültesi/Fizyoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Farmakoloji ve Klinik Farmakoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-5600-8162tr_TR
dc.contributor.orcid0000-0001-9496-1475tr_TR
dc.contributor.researcheridAAC-9702-2019tr_TR
dc.contributor.researcheridAAG-6956-2021tr_TR
dc.contributor.researcheridAAH-1571-2021tr_TR
dc.contributor.scopusid57192959734tr_TR
dc.contributor.scopusid6507468595tr_TR
dc.contributor.scopusid8895544100tr_TR
dc.contributor.scopusid6603687024tr_TR
dc.date.accessioned2021-10-01T13:00:12Z
dc.date.available2021-10-01T13:00:12Z
dc.date.issued2006-11-06
dc.description.abstractIn the present study, we investigated the role of the central cholinergic system in mediating the pressor effect of intracerebroventricularly administrated U-46619, a thromboxane A2 (TxA2) analog, in hemorrhaged hypotensive rats. Hemorrhage was performed by withdrawing a total volume of 2.1 ml of blood per 100 g body weight over a period of 10 min. Intracerebroventricular (i.c.v.) injection of U-46619 (0.5, 1, 2 mu g) produced a dose- and time-dependent increase in arterial pressure and reversed the hypotension of this condition. Hemorrhage caused small increases in extracellular hypothalamic acetylcholine and choline levels. Intracerebroventricular administration of U-46619 (1 mu g) further increased the levels of extracellular acetylcholine and choline by 57% and 41%, respectively. Pretreatment with SQ29548 (8 pg; i.c.v.), a selective TxA2 receptor antagonist, completely abrogated the effects of subsequent injection of U-46619 (1 mu g; i.c.v.) on arterial pressure and extracellular acetylcholine and choline levels. Pretreatment with mecamylamine (50 pg; i.c.v.), a cholinergic nonselective nicotinic receptor antagonist, attenuated the pressor effect of U46619 (1 mu g, ix.v.) in hemorrhaged rats whereas pretreatment with atropine (10 mu g; i.c.v.), a cholinergic nonselective muscarinic receptor antagonist, had no effect. Interestingly, pretreatment of rats with methyllycaconitine (10 IAg; i.c.v.) or a-bungarotoxin (10 mu g; i.c.v.), selective antagonists of alpha-7 subtype nicotinic acetylcholine receptors (alpha 7nAChRs), partially abolished the pressor effect of U-46619 (1 vg; i.c.v.) in the hypotensive condition. Pretreatment with a combination of mecamylamine plus methyllycaconitine or mecamylamine plus a-bungarotoxin attenuated the reversal effect of U-46619, but only to the same extent as pretreatment with either antagonist alone. In conclusion, i.c.v. administration of U-46619 restores arterial pressure and increases posterior hypothalamic acetylcholine and choline levels by activating central TxA2 receptors in hemorrhaged hypotensive rats. The activation of central nicotinic cholinergic receptors, predominantly alpha 7nAChRs, partially acts as a mediator in the pressor responses to i.c.v. injection of U-46619 under these conditions.en_US
dc.identifier.citationYalçın, M. vd. (2006). ''Activation of the central cholinergic system mediates the reversal of hypotension by centrally administrated U-46619, a thromboxane A2 analog, in hemorrhaged rats''. Brain Research, 1118(1), 43-51.en_US
dc.identifier.endpage51tr_TR
dc.identifier.issn0006-8993
dc.identifier.issn1872-6240
dc.identifier.issue1tr_TR
dc.identifier.pubmed16962568tr_TR
dc.identifier.scopus2-s2.0-33750284887tr_TR
dc.identifier.startpage43tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.brainres.2006.08.014
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0006899306023699
dc.identifier.urihttp://hdl.handle.net/11452/22186
dc.identifier.volume1118tr_TR
dc.identifier.wos000242147400006tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.journalBrain Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNeurosciences & neurologyen_US
dc.subjectPosterior hypothalamusen_US
dc.subjectTxA2en_US
dc.subjectHemorrhagic shocken_US
dc.subjectCholinergicen_US
dc.subjectNicotinicen_US
dc.subjectA7nAChRen_US
dc.subjectRestorationen_US
dc.subjectMecamylamineen_US
dc.subjectInvolvementen_US
dc.subjectProstaglandinsen_US
dc.subjectResponsesen_US
dc.subjectA(2)en_US
dc.subjectInjected U-46619en_US
dc.subjectProstanoid receptorsen_US
dc.subjectAdrenomedullary outflowen_US
dc.subjectBlood-pressureen_US
dc.subject.emtreeThromboxane A2 receptoren_US
dc.subject.emtreeMethyllycaconitineen_US
dc.subject.emtreeMecamylamineen_US
dc.subject.emtreeCholineen_US
dc.subject.emtreeAtropineen_US
dc.subject.emtreeAlpha bungarotoxinen_US
dc.subject.emtreeAcetylcholineen_US
dc.subject.emtree15 hydroxy 11alphaen_US
dc.subject.emtree9 alpha epoxymethanoprosta 5,13 dienoic aciden_US
dc.subject.emtree7 [3 [(4 phenylsemicarbazido)methyl] 7 oxabicyclo[2.2.1]hept 2 yl] 5 heptenoic aciden_US
dc.subject.emtreeRaten_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeNonhumanen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeHypotensionen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeCholinergic systemen_US
dc.subject.emtreeBlood volumeen_US
dc.subject.emtreeBlood volumeen_US
dc.subject.emtreeBleedingen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeArterial pressureen_US
dc.subject.emtreeAnimal modelen_US
dc.subject.emtreeAnimal experimenten_US
dc.subject.meshBlood Pressureen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAcetylcholineen_US
dc.subject.mesh15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic aciden_US
dc.subject.meshVasoconstrictor agentsen_US
dc.subject.meshTime factorsen_US
dc.subject.meshThromboxane A2en_US
dc.subject.meshCholinergic fibersen_US
dc.subject.meshReceptors, thromboxane A2, prostaglandin H2en_US
dc.subject.meshReceptors, nicotinicen_US
dc.subject.meshRats, sprague-dawleyen_US
dc.subject.meshRatsen_US
dc.subject.meshNicotinic antagonistsen_US
dc.subject.meshNeural pathwaysen_US
dc.subject.meshMaleen_US
dc.subject.meshInjections, intraventricularen_US
dc.subject.meshHypothalamus, posterioren_US
dc.subject.meshHypotensionen_US
dc.subject.meshHydrazinesen_US
dc.subject.meshHemorrhageen_US
dc.subject.meshExtracellular fluiden_US
dc.subject.meshExtracellular fluiden_US
dc.subject.meshDose-response relationship, drugen_US
dc.subject.meshDisease models, animalen_US
dc.subject.scopusHistamine H4 Receptors; Thioperamide; Chlorpheniramine Maleateen_US
dc.subject.wosNeurosciencesen_US
dc.titleActivation of the central cholinergic system mediates the reversal of hypotension by centrally administrated U-46619, a thromboxane A2 analog, in hemorrhaged ratsen_US
dc.typeArticle
dc.wos.quartileQ3en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus